A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.

doi:10.3324/haematol.2015.140988

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.

Haematologica - 1 Aug 2016

Thépot Sylvain, Ben Abdelali Raouf, Chevret Sylvie, Renneville Aline, Beyne-Rauzy Odile, Prébet Thomas, Park Sophie, Stamatoullas Aspasia, Guerci-Bresler Agnes, Cheze Stéphane, Tertian Gérard, Choufi Bachra, Legros Laurence, Bastié Jean Noel, Delaunay Jacques, Chaury Marie Pierre, Sanhes Laurence, Wattel Eric, Dreyfus Francois, Vey Norbert, Chermat Fatiha, Preudhomme Claude, Fenaux Pierre, Gardin Claude

Abstract excerpt

The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to azacitidine in this setting are not well known. We prospectively compared the outcomes of patients, all of them having the characteristics of this subset of lower-risk myelodysplastic syndrome, if...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to Cytogenetic Analysis

Share to Drug Resistance

Share to Erythropoietin

Share to Myelodysplastic Syndromes

Share to Recombinant Proteins

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 27229713
DOI: 10.3324/haematol.2015.140988
PMCID: PMC4967570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.PMID 27229713Read ↗

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trialSemantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.Semantic proximity Read ↗

Therapy for lower-risk MDS.Semantic proximity Read ↗

Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.Semantic proximity Read ↗

Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.Semantic proximity Read ↗

ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.Semantic proximity Read ↗

ASXL1 Mutations with Serum EPO Levels Predict a Poor Response to Darbepoetin Alfa in Lower-Risk MDS: W-JHS MDS01 TrialSemantic proximity Read ↗

Lowering the boom on lower-risk myelodysplastic syndromes.Semantic proximity Read ↗

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.Semantic proximity Read ↗

[Clinical features of SF3B1 mutation in patients with myelodysplastic syndrome with excess blasts].Semantic proximity Read ↗

Survival of myelodysplastic syndrome patients after azacitidine therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.